NO20031450L - Fumarsyrederivater som NF-kappa B inhibitorer - Google Patents

Fumarsyrederivater som NF-kappa B inhibitorer

Info

Publication number
NO20031450L
NO20031450L NO20031450A NO20031450A NO20031450L NO 20031450 L NO20031450 L NO 20031450L NO 20031450 A NO20031450 A NO 20031450A NO 20031450 A NO20031450 A NO 20031450A NO 20031450 L NO20031450 L NO 20031450L
Authority
NO
Norway
Prior art keywords
kappa
inhibitors
fumaric acid
acid derivatives
derivatives
Prior art date
Application number
NO20031450A
Other languages
English (en)
Norwegian (no)
Other versions
NO20031450D0 (no
Inventor
Rajendra Kumar Joshi
Hans-Peter Strebel
Peter Petzelbauer
Original Assignee
Fumapharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fumapharm Ag filed Critical Fumapharm Ag
Publication of NO20031450D0 publication Critical patent/NO20031450D0/no
Publication of NO20031450L publication Critical patent/NO20031450L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
NO20031450A 2001-01-12 2003-03-28 Fumarsyrederivater som NF-kappa B inhibitorer NO20031450L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10101307A DE10101307A1 (de) 2001-01-12 2001-01-12 Fumarsäurederivate als NF-kappaB-Inhibitor
PCT/EP2002/000108 WO2002055067A2 (de) 2001-01-12 2002-01-08 Fumarsäurederivate als nf-kappab-inhibitor

Publications (2)

Publication Number Publication Date
NO20031450D0 NO20031450D0 (no) 2003-03-28
NO20031450L true NO20031450L (no) 2003-09-12

Family

ID=7670424

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031450A NO20031450L (no) 2001-01-12 2003-03-28 Fumarsyrederivater som NF-kappa B inhibitorer

Country Status (22)

Country Link
US (2) US20040054001A1 (pl)
EP (1) EP1408947A2 (pl)
JP (2) JP2004528281A (pl)
CN (1) CN1520291A (pl)
AU (1) AU2002244638B2 (pl)
BG (1) BG107829A (pl)
BR (1) BR0206381A (pl)
CA (1) CA2428075A1 (pl)
CZ (1) CZ20031918A3 (pl)
DE (1) DE10101307A1 (pl)
EE (1) EE200300281A (pl)
HU (1) HUP0302650A3 (pl)
IL (1) IL156849A0 (pl)
MX (1) MXPA03006248A (pl)
NO (1) NO20031450L (pl)
NZ (1) NZ525148A (pl)
PL (1) PL363603A1 (pl)
RU (1) RU2282440C2 (pl)
SK (1) SK8252003A3 (pl)
WO (2) WO2002055066A1 (pl)
YU (1) YU55903A (pl)
ZA (1) ZA200305343B (pl)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10217314A1 (de) * 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
DE10360869A1 (de) * 2003-09-09 2005-04-07 Fumapharm Ag Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma
DE602004010531T2 (de) 2003-09-09 2008-07-03 Fumapharm Ag Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma
DE10342423A1 (de) * 2003-09-13 2005-04-14 Heidland, August, Prof. Dr.med. Dr.h.c. Verwendung von Fumarsäurederivaten zur Prophylaxe und zur Behandlung von Genomschäden
PT2316430E (pt) 2004-10-08 2012-06-26 Forward Pharma As Composições farmacêuticas de libertação controlada compreendendo um éster de ácido fumárico
US20070142905A1 (en) * 2005-12-16 2007-06-21 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
RU2313337C1 (ru) * 2006-05-18 2007-12-27 Государственное учреждение Научный центр медицинской экологии Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук Лекарственное средство для лечения хронического гепатита в
WO2008070121A1 (en) * 2006-12-06 2008-06-12 Cornell Research Foundation, Inc. Intermediate duration neuromuscular blocking agents and antagonists thereof
HRP20220902T3 (hr) 2007-02-08 2022-10-14 Biogen Ma Inc. Pripravci i njihova upotreba u liječenju multiple skleroze
EP3135282A1 (en) * 2007-02-08 2017-03-01 Biogen MA Inc. Neuroprotection in demyelinating diseases
KR20090028047A (ko) * 2007-09-13 2009-03-18 경북대학교 산학협력단 디메틸푸마레이트의 신규 용도
DE102008030023A1 (de) * 2008-06-16 2009-12-17 Eberhard-Karls-Universität Tübingen Universitätsklinikum Arzneimittel zur Behandlung einer durch Parasiten verursachten Krankheit
PL2334378T3 (pl) 2008-08-19 2014-09-30 Xenoport Inc Proleki wodorofumaranu metylu, ich kompozycje farmaceutyczne i sposoby zastosowania
UA112975C2 (uk) 2009-01-09 2016-11-25 Форвард Фарма А/С Фармацевтичний склад, що містить в матриці, яка піддається ерозії, один або більше ефірів фумарової кислоти
WO2010107488A1 (en) 2009-03-17 2010-09-23 Cornell University Reversible nondepolarizing neuromuscular blockade agents and methods for their use
AU2010242064A1 (en) * 2009-04-29 2011-11-17 Biogen Ma Inc. Treatment of neurodegeneration and neuroinflammation
US9220700B2 (en) 2009-08-19 2015-12-29 Cornell University Cysteine for physiological injection
DK2718257T3 (en) 2011-06-08 2018-02-12 Biogen Ma Inc PROCEDURE FOR THE PREPARATION OF HIGH PURITY Crystalline DIMETHYL FUMARATE
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
CA2864040A1 (en) 2012-02-07 2013-08-15 Xenoport, Inc. Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
AU2013305684B2 (en) 2012-08-22 2016-11-24 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
US20140171504A1 (en) * 2012-12-14 2014-06-19 Georgia Regents Research Institute, Inc. Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters
ES2733961T3 (es) 2012-12-21 2019-12-03 Biogen Ma Inc Derivados de fumarato sustituidos con deuterio
KR101379427B1 (ko) * 2013-02-13 2014-03-28 경북대학교병원 디메틸푸마레이트를 유효성분으로 포함하는 신섬유증의 예방 또는 치료용 조성물
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
KR101814474B1 (ko) 2013-03-14 2018-01-12 엘커메스 파마 아일랜드 리미티드 푸마레이트의 프로드럭 및 다양한 질환을 치료하는데 있어서의 이들의 용도
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
EP3041467A1 (en) 2013-09-06 2016-07-13 XenoPort, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
CN104434904B (zh) * 2013-09-22 2018-09-04 深圳翰宇药业股份有限公司 一种复方微丸胶囊的制备方法及其制备的复方微丸胶囊
HRP20210468T1 (hr) * 2013-12-12 2021-05-14 Almirall S.A. Farmaceutski pripravci koji sadrže dimetil fumarat
US10172794B2 (en) * 2013-12-13 2019-01-08 Biogen Ma Inc. Controlled release dosage form for once daily administration of dimethyl fumarate
TWI572358B (zh) 2013-12-20 2017-03-01 財團法人生物技術開發中心 α－烯醇化酶特異性抗體及其使用在免疫疾病之方法
WO2015127450A1 (en) 2014-02-24 2015-08-27 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
WO2015128492A1 (en) * 2014-02-28 2015-09-03 Maghazachi Azzam A Monomethyl- and dimethylfumarate for nk cell activation
AU2015222880B2 (en) 2014-02-28 2016-11-24 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
CN104027311A (zh) * 2014-05-09 2014-09-10 万特制药(海南)有限公司 一种含有富马酸二甲酯的肠溶缓释微丸
WO2016061393A1 (en) 2014-10-15 2016-04-21 Xenoport, Inc. Fumarate compounds, pharmaceutical compositions, and methods of use
WO2016074684A1 (en) * 2014-11-11 2016-05-19 Syddansk Universitet Fumaric acid derivatives for medical use
MA40982A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
CN104523602B (zh) * 2014-12-12 2018-06-05 广东东阳光药业有限公司 一种富马酸二甲酯肠溶微片及其制备方法
CN105797154B (zh) * 2014-12-31 2020-03-10 中国科学院上海生命科学研究院 软骨干细胞的分离及其应用
EP3270911A4 (en) * 2015-03-17 2018-08-29 Hetero Labs Limited Pharmaceutical compositions of dimethyl fumarate
CA2989581A1 (en) 2015-06-17 2016-12-22 Biogen Ma Inc. Dimethyl fumarate particles and pharmaceutical compositions thereof
US10213411B2 (en) 2015-08-27 2019-02-26 Vijaykumar Rajasekhar Use of prodrugs of fumarates in treating heart failure diseases
WO2017060400A1 (en) 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
DE102015117882A1 (de) * 2015-10-21 2017-04-27 Mehrdad Ghashghaeinia Pharmazeutische Zusammensetzung
US10463642B2 (en) 2016-02-01 2019-11-05 Vijaykumar Rajasekhar Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate
BR112018016300A2 (pt) * 2016-02-12 2018-12-26 Univ Zuerich fumarato de dimetila (dmf) para prevenção ou tratamento de gota, acne, diabetes, vitiligo e/ou pioderma gangrenoso
CN106265621B (zh) * 2016-09-19 2019-05-17 苏州大学 富马酸二甲酯在制备预防和治疗移植物抗宿主病及移植物抗白血病药物中的应用
JP6866603B2 (ja) * 2016-10-12 2021-04-28 三菱ケミカル株式会社 樹脂組成物、防汚塗料組成物および樹脂組成物の製造方法
CN107088190A (zh) * 2016-11-23 2017-08-25 中南大学湘雅医院 富马酸酯在制备治疗肝病药物中的应用
CN107021996B (zh) * 2017-05-24 2020-02-14 中国海洋大学 一种短肽、其应用以及由其得到的抗菌组合物
WO2018234584A1 (en) 2017-06-23 2018-12-27 Almirall, S.A. PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE
WO2020094767A1 (en) 2018-11-08 2020-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of nrf2 activators for the treatment of staphylococcus aureus infections
EP4578850A3 (en) 2019-04-17 2025-10-15 Myto Therapeutics, Inc. Prodrugs of monomethyl fumarate
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
WO2022038365A2 (en) * 2020-08-21 2022-02-24 Sitryx Therapeutics Limited Novel compounds
WO2024047248A1 (en) 2022-09-02 2024-03-07 Institut National de la Santé et de la Recherche Médicale Use of nrf2 activators for the treatment of cerebral small vessel disease

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2993837A (en) * 1959-07-13 1961-07-25 Frosst & Co Charles E Enteric coated tablets
FR6808M (pl) * 1967-09-22 1969-03-24
US3832287A (en) * 1972-03-02 1974-08-27 Lilly Co Eli Dipeptide antibiotic and method for the production thereof
DE3127432A1 (de) * 1981-07-11 1983-02-03 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von fumarsaeuremonoester
US5149695A (en) * 1985-01-15 1992-09-22 Speiser Peter P Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same
CH664150A5 (de) * 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
JPS61194020A (ja) * 1985-02-22 1986-08-28 Dai Ichi Seiyaku Co Ltd 網膜症治療剤
US5242905A (en) * 1987-09-04 1993-09-07 Dexter Chemical Corporation Pharmaceutical compositions for the treatment of psoriasis
US5214196A (en) * 1987-09-04 1993-05-25 Dexter Chemical Corporation Diethyl ester of di-glycyl fumaramide
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
US5424332A (en) * 1987-10-19 1995-06-13 Speiser; Peter P. Pharmaceutical composition and process for the production thereof
WO1992012952A1 (en) * 1991-01-18 1992-08-06 Dexter Chemical Corporation Malic acid derivatives and compositions for the treatment of psoriasis
IT1251166B (it) * 1991-08-09 1995-05-04 Chiesi Farma Spa Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono
US5763408A (en) * 1992-06-03 1998-06-09 Fuji Photo Film Co., Ltd. Amino acid derivatives and application thereof
WO1994028883A1 (en) * 1993-06-08 1994-12-22 Brown Raymond K Therapeutic compositions and methods of use
US5407772A (en) * 1993-11-30 1995-04-18 Xerox Corporation Unsaturated polyesters
IL110380A0 (en) * 1994-07-20 1994-10-21 Agis Ind 1983 Ltd Antiviral topical pharmaceutical compositions
US5589504A (en) * 1994-07-26 1996-12-31 Cornell Research Foundation, Inc. Treatment of newborn jaundice
EP2298350A3 (en) * 1996-07-26 2011-06-08 Susan P. Perrine Composition comprising an inducing agent and an anti-viral agent for the treatment of viral disorders
CA2275256A1 (en) * 1996-12-18 1998-06-25 Basf Aktiengesellschaft Heterocyclic carboxylic acid derivatives, the production and use thereof as endothelin receptor antagonists
WO1998027970A2 (en) * 1996-12-24 1998-07-02 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
US5972363A (en) * 1997-04-11 1999-10-26 Rohm And Haas Company Use of an encapsulated bioactive composition
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19735410A1 (de) * 1997-08-14 1999-02-18 Basf Ag 2-{3-[4-(2-t-Butyl-6-trifluormethylpyrimidin-4-yl)piperazin-1-yl]propylmercapto}pyrimidin-4-ol-fumarat
DE19814358C2 (de) * 1998-03-31 2002-01-17 Fumapharm Ag Muri Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19848260C2 (de) * 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10000577A1 (de) * 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
RU2160589C1 (ru) * 2000-05-18 2000-12-20 Алекс Кашлинский Средство для снижения алкогольного опьянения, предупреждения и снятия алкогольной интоксикации и похмельного синдрома и способ снижения алкогольного опьянения, предупреждения и снятия алкогольной интоксикации и похмельного синдрома с использованием этого средства

Also Published As

Publication number Publication date
SK8252003A3 (en) 2003-12-02
JP2004528281A (ja) 2004-09-16
EE200300281A (et) 2003-10-15
PL363603A1 (pl) 2004-11-29
MXPA03006248A (es) 2004-04-02
BG107829A (bg) 2004-12-30
HUP0302650A3 (en) 2009-08-28
YU55903A (sh) 2006-08-17
CN1520291A (zh) 2004-08-11
US20040054001A1 (en) 2004-03-18
ZA200305343B (en) 2004-08-17
DE10101307A1 (de) 2002-08-01
WO2002055066A1 (de) 2002-07-18
US20080233185A1 (en) 2008-09-25
JP2009073854A (ja) 2009-04-09
WO2002055067A3 (de) 2004-02-26
CZ20031918A3 (en) 2004-04-14
EP1408947A2 (de) 2004-04-21
BR0206381A (pt) 2004-08-03
CA2428075A1 (en) 2002-07-18
NZ525148A (en) 2006-06-30
RU2282440C2 (ru) 2006-08-27
NO20031450D0 (no) 2003-03-28
AU2002244638B2 (en) 2005-05-05
HUP0302650A2 (hu) 2003-11-28
RU2003124751A (ru) 2005-01-10
WO2002055067A2 (de) 2002-07-18
IL156849A0 (en) 2004-02-08

Similar Documents

Publication Publication Date Title
NO20031450L (no) Fumarsyrederivater som NF-kappa B inhibitorer
NO20030867D0 (no) Hydroksamderivater anvendelig som deacetylaseinhibitorer
NO20034044D0 (no) Metallproteinase-inhibitorer
NO20033618D0 (no) Ftalayinon-piperidino-derivater som PDE-4-inhibitorer
NO20033593D0 (no) Kinazoliner som MMP-13 inhibitorer
NO20021239D0 (no) Pteridinoner som kinase-inhibitorer
NO20030055L (no) Colchinolderivater som angiogenese inhibitorer
DE60234125D1 (de) E inhibitoren
NO20023828L (no) Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
NO20041887L (no) Benzomidazoler anvendelige som proteinkinase-inhibitorer
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
NO20014483D0 (no) Aminderivater som proteaseinhibitorer
DK1460066T3 (da) Piperazinforbindelse som tachykinin-inhibitorer
ATE524441T1 (de) Vla-4-inhibitoren
NO20015065D0 (no) Pyrazolobenzodiazepiner som CDK2-inhibitorer
NO20024997D0 (no) 2-guanidino-4-arylkinazoliner som NHE-3-inhibitorer
NO20034032L (no) Metallproteinase-inhibitorer
NO20050665L (no) Pyrrolidonderivater som MAOE inhibitoere
DK1311488T3 (da) Substituerede imidazoler som tafia-inhibitorer
EE200400023A (et) Uued sulfoonhappe derivaadid
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
NO20042938L (no) Nitrogenholdige forbindelser som korrosjonsinhibitorer
NO20021959L (no) Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
FI20002044A0 (fi) Comt-entsyymiä estäviä naftaleenijohdannaisia

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application